Home › Research › Topics › placebo-controlled
placebo-controlled
804 studies tagged placebo-controlled, dated 1986-01-01 to 2026-09-22. Bibliography: BibTeX (.bib) · RIS (.ris)
Newest in this topic
- Ceperognastat in Early Symptomatic Alzheimer Disease: A Randomized Clinical Trial 2026-09-22
- Varenicline as a Repurposable Drug Candidate for ADRD Prevention 2026-09-20
- Antihypertensive Medication Class and Incident Alzheimers Disease and Related Dementias: External Replication Across Two Independent Healthcare Data Sources-the Vanderbilt EHR Synthetic Derivative and US Medicare Claims 2026-09-17
Studies
804 studies carry this tag.
Date range
1986 to 2026
Top journals
- Neurology 66
- The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 35
- JAMA 24
- JAMA neurology 23
- Alzheimer's research & therapy 21
333 journals in all.
Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.
-
No benefits were demonstrated for secondary clinical end points.
-
ObjectiveEffective strategies to prevent Alzheimers disease and related dementias (ADRD) are limited.
-
ObjectiveTo externally replicate and extend prior findings across two structurally independent healthcare data sources, evaluating whether predominant use of antihypertensive medications that stimulate versus inhibit angiotensin II type 2 and type 4 receptor signaling is associated with risk of incident ADRD.
-
INTRODUCTIONSleep-dependent memory consolidation is impaired early in Alzheimers disease (AD).
-
Este ensayo tiene como objetivo analizar la eficacia del lecanemab como terapia modificadora de la enfermedad de Alzheimer (EA).
-
BackgroundNon-pharmacological interventions may enhance motor-cognitive integration in prodromal Alzheimers disease (pAD).
-
Pivotal trials demonstrated statistically significant but modest average slowing of decline: Clarity AD showed a 0.45-point between-group difference in CDR-SB worsening at 18 months, and TRAILBLAZER-ALZ 2 showed a 3.25-point iADRS difference in the low/medium-tau population at 76 weeks.
-
Monoamine oxidase B (MAO-B) is a high-density protein located mainly in astrocytes that influences mitochondrial function and transition to astrogliosis.
-
27/100
La aprobación de lecanemab y donanemab para el tratamiento de la enfermedad de Alzheimer temprana plantea nuevos desafíos para la neurología vascular, principalmente por la aparición de anomalías en las imágenes relacionadas con el amiloide (ARIA).
-
Rapamycin, an FDA-approved inhibitor of the mammalian target of rapamycin (mTOR) pathway, has demonstrated promising anti-aging and neuroprotective effects.
-
There is high unmet need in dementia with Lewy bodies (DLB).
-
ε4 noncarriers and those with lower baseline amyloid burden.
-
In this real-life crossover study, THC/CBD oil did not show superiority over placebo in reducing agitation in severe dementia.
-
Alzheimer's disease is a multifactorial neurodegenerative disorder characterized by amyloid- β aggregation, oxidative stress, neuroinflammation, tau hyperphosphorylation, and cholinergic dysfunction.
-
Lecanemab, an amyloid-targeting monoclonal antibody, was recently approved for early symptomatic Alzheimer's disease in South Korea.
-
No amyloid-related imaging abnormalities occurred.
-
These findings support the use of triazole scaffolds as a unique and versatile framework for developing multifunctional anti‐Alzheimer agents with perceived disease‐modifying activity.
-
Alzheimer’s disease (AD) is characterized by progressive accumulation of amyloid-β (Aβ) peptides, initiating a pathological cascade from soluble monomers to toxic oligomers, protofibrils, fibrils, and ultimately extracellular amyloid plaques that contribute to synaptic dysfunction and neuronal degeneration.
-
Lecanemab is a humanized monoclonal antibody that binds soluble brain amyloid-β protein, promoting its removal and slowing the underlying process of Alzheimer disease. 1 This mechanism aligns with the amyloid hypothesis, a debated model of Alzheimer disease pathogenesis.1 Only patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer disease are eligible for lecanemab treatment.
-
Isolated rapid eye movement sleep behavior disorder (iRBD) is a major prodromal marker of α-synucleinopathies, often preceding the clinical onset of Parkinson's disease, dementia with Lewy bodies, or multiple system atrophy.
-
-glycans found at the N304 site of lecanemab of the heavy chain.
-
HIIT alone and in combination with CBD treatment significantly improved cognitive impairment induced by AD.
-
This study aimed to identify lipid species associated with MPH response and explore lipid pathway disruptions in responders versus non-responders.
-
Donanemab, a monoclonal antibody targeting the insoluble form of β-amyloid found in plaques, significantly slows cognitive and functional decline of AD in participants with mild cognitive impairment (MCI) or mild AD-related dementia.
-
BackgroundLecanemab is the first approved disease-modified therapy in Japan for patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) or mild AD dementia (AD-D).ObjectiveThis study aims to evaluate the social value of lecanemab in Japan.
-
Although β-site APP-cleaving enzyme 1 (BACE1) and secretase inhibitors did not achieve success in clinical trials because of mechanism-based toxicity and cognitive impairment, new monoclonal antibodies such as lecanemab and donanemab have shown high amyloid plaque clearance and reduced cognitive deterioration.
-
Guidelines recommend limiting antipsychotic treatment to short-term use ( Methods Using UK primary care data from the Clinical Practice Research Datalink, linked with hospital and mortality data from Jan 1, 1998, to March 31, 2021, we emulated two sets of target trials, one after 12 weeks of antipsychotic treatment and another after 24 weeks of antipsychotic treatment, to compare continuing treatment versus tapering treatment and continuing treatment versus abrupt discontinuation of treatment.
-
Ginsenosides are the primary active constituents derived from the dried roots of ginseng, a staple in traditional Chinese medicine.
-
Among 45,651 patients, 311 delirium events occurred among continuous users and 84 among early discontinuers, corresponding to incidence rates of 66 and 112 events per 10,000 person-years, respectively.
-
Compared with conventional activities, GDRT resulted in significantly greater reductions in overall BPSD (r = 0.56, p = .001) and caregiver burden (r = 0.44, p = .011).
-
Synthesis methods We meta-analysed results for each outcome within each comparison using the inverse variance method and the random-effects model.
-
Im Zuge der Alzheimerkrankheit lagern sich Beta-Amyloid-Plaques im Gehirn ab.
-
Donanemab provides clinical benefits but is unlikely to be cost-effective under current Australian thresholds.
-
Donanemab increased total healthcare costs ($300,689 vs. $178,121) and societal costs ($389,113 vs. $283,618) compared with standard care per capita, while improving health outcomes (4.38 vs. 4.01 QALYs) per capita.
-
Between May 18, 2021, and Sept 8, 2023, 9981 participants were screened, of whom 3808 were randomly assigned; 1855 in evoke (semaglutide, n=928; placebo, n=927) and 1953 in evoke+ (semaglutide, n=976; placebo, n=977).
-
Animal studies indicate that Dang Gui Shao Yao San (DGSYS) may enhance cognitive function in VaD models through mechanisms such as antioxidation and the enhancement of cerebral blood flow.
-
Bacopa consumption is known to enhance cognitive performance in healthy individuals and is associated with alterations in pathways related to branched-chain and aromatic amino acid biosynthesis.
-
In 2018, France withdrew reimbursement for cholinesterase inhibitors (ChEIs) in Alzheimer's disease, citing modest efficacy, lack of long-term benefit, and safety concerns.
-
Plain Language SummaryWhat is this summary about?
-
46/100
GLP-1RA use was associated with a significantly lower risk of dementia [hazard ratio (HR) 0.80, 95% confidence interval (CI) 0.71-0.91, P = .001] and Alzheimer's disease (HR 0.76, 95% CI 0.59-0.98, P = .033) compared with DPP4i use.
-
Alzheimer's disease (AD) manifests as a chronic neurodegenerative syndrome featuring cognitive impairment alongside characteristic neuropathological markers: amyloid-beta (Aβ) plaques and tau-associated neurofibrillary tangles.
-
72/100
Of the 120 participants (mean age, 71.4 [SD, 8.6] years; 55% were female), 93 (77.5%) completed the trial.
-
64/100
A brief DMA combined with plasma pTau217 identifies a subset of cognitively unimpaired, amyloid-positive older adults at highest risk for cognitive and biomarker progression.
-
Main results We included 82 studies with 10,613 participants; 72 studies with 9783 participants provided extractable data.
-
Alzheimer disease (AD) is a major health issue of global concern whereby there are minimal treatment options.
-
Alzheimer disease (AD) is a major health issue of global concern whereby there are minimal treatment options.
-
BackgroundCholinesterase inhibitors (ChEIs) are cornerstones of the symptomatic treatment of Alzheimer's disease (AD) and dementia with Lewy bodies (DLB) and are also prescribed for vascular dementia (VaD).
-
Alzheimer's disease (AD) is a neurodegenerative disorder involving the amyloid-β plaque deposition, tau pathology, synaptic dysfunction, and impairment in cognition.
-
A significant median Centiloid reduction of 30.9 was observed, with a 24.1% amyloid PET negativity rate after six months.
-
Treatment options for dementia mainly comprise of symptomatic treatment, as no disease-modifying therapy currently exists that directly reduces the pathology.
From across this tag
9 of the 795 studies in this tag, picked by a fixed rule (a hash of each study's address), not by score or date; each page of this list shows a different 9. The same 9 appear here every time.
- Effect of Levetiracetam on Cognition in Patients With Alzheimer Disease With and Without Epileptiform Activity: A Randomized Clinical Trial
- Melatonin for treatment of sundowning in elderly persons with dementia - a preliminary study
- Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis
- Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation
- Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: a randomized clinical trial
- A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer's disease
- Brexpiprazole treatment for agitation in Alzheimer's dementia: A randomized study
- Effects of the Finnish Alzheimer disease exercise trial (FINALEX): a randomized controlled trial
- The effect of curcumin (turmeric) on Alzheimer's disease: An overview